New Lipid Guidelines and the Role of PCSK9 Inhibition

Details & Video

Learn how to apply the new CCS Lipid Guidelines in your practice.

Video Time: 36 minutes
Program Interactivity: 10 min
Accreditation-CME Credits: This activity is approved for .75 CME credits: RCPSC MOC Section 1; CFPC Mainpro-M1.
Target Audience: General Practitioners, Cardiologists, Internists, Endocrinologists
Program available until: June 14, 2017
Program Preview
Click image above to play the program preview.
To watch the full program, please login or register

Overview & Objectives

New Lipid Guidelines and the Role of PCSK9 Inhibition

Target Audience: General Practitioners, Cardiologists, Internists, Endocrinologists.

Program Outline: The CCS Lipid Guidelines are the first in the world to be developed since the publication of the IMPROVE-IT study and the introduction of PCSK9 inhibitors into the marketplace. While evidence accrues that lower is better when it comes to LDL-C levels, particularly in high risk patients, many patients are unable to achieve current LDL-C targets with statin monotherapy. The additional LDL-C lowering and clinical benefits of adding ezetimibe to statin therapy are modest at best.

PCSK9 inhibitors offer robust LDL-C lowering with an excellent tolerability profile. This program will review the new Canadian Lipid Guidelines, updates in statin intolerance, and explore how PCSK9 inhibitors fit within guideline recommendations. Selection of the appropriate patient, practical use of PCSK9 inhibitors, and their long-term safety will also be discussed. Real-life case examples will accentuate the discussions.

Learning Objectives:
  1. To discuss management options for the high-risk patient whose LDL-C remains above target despite statin therapy
  2. To evaluate the role of  non-statin drugs in lipid management and risk reduction
  3. To review updates in the latest lipid guidelines



Accreditation



This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. This program is approved by the Canadian Cardiovascular Society for a maximum of 1 credit.





Continuing Professional Development (CPD)
Faculty of Medicine, McGill University



This event is approved for up to 0.75 credits by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME).

This program meets the accreditation criteria of the College of Family Physicians of Canada for MAINPRO-M1 credits. Members of the American Academy of Family Physicians are eligible to receive credit hours for attendance at this meeting due to a reciprocal agreement with the College of Family Physicians of Canada.

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Each physician should claim only credit commensurate with the extent of their participation in the activity.

Planning Committee

Planning Committee

Milan Gupta
Milan Gupta
FRCPC, FACC
Brampton, ON


G.B. John Mancini
G.B. John Mancini
MD, FRCPC, FACP, FACC
Vancouver, BC


Jacques Genest
Jacques Genest
MD, CM, FRCPC, FACC, FAHA
Montréal, QC


Vivien Brown
Vivien Brown
MDCM, CCFP, FCFP, NCMP
Toronto, ON


Robert Dufour
Robert Dufour
M.D., M.Sc.
Montréal, QC


Daniel Ngui
Daniel Ngui
BSc (P.T), MD, CFPC, FCFP
Vancouver, ON


Faculty

Faculty

Milan Gupta
Chair
Milan Gupta
FRCPC, FACC

Associate Clinical Professor, Dep’t of Medicine
McMaster University

Assistant Professor, Dep’t of Medicine
University of Toronto

Medical Director
Canadian Cardiovascular Research Network

View disclosures

Brampton, ON
G.B. John Mancini
G.B. John Mancini
MD, FRCPC, FACP, FACC

Professor of Medicine,
University of British Columbia

Department of Medicine,
Division of Cardiology

Research Director,
Division of Cardiology

Director,
Cardiovascular Imaging Research Core Laboratory (CIRCL)

Vancouver, BC
Jacques Genest
Jacques Genest
MD, CM, FRCPC, FACC, FAHA

Professor and Novartis Chair in Medicine,
McGill University

Scientific Director,
Center for Innovative Medicine,
McGill University Health Center/Royal Victoria Hospital

Montréal, QC

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
&
Presenter
Introduction2:15
Milan Gupta
Lipid Guidelines in 20168:25
Milan Gupta
Statin Intolerance10:23
G.B. John Mancini
Familial Hypercholesterolemia4:19
Jacques Genest
Lowering LDL: Beyond Statins5:04
Jacques Genest
Discussion 5:09
Milan Gupta, Jacques Genest, G.B. John Mancini


Sponsorship

CCRN sm

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from::

Amgen Canada

Links & Resources

Links:

Statin Intolerance Papers

  • Mancini et al 2011 CJC- Mancini et al. Can J Cardiol 2011;27;635-62
  • Mancini et al 2013 CJC- Mancini et al. Can J Cardiol 2013;29:1553-1568
  • Mancini et al 2016 CJC- Mancini et al. Can J Cardiol 2016; 10:1016
  • Statin associated muscle symptoms 2014 ESC- Stroes et al. Eur Heart J 2015;36;1012-22

FH Papers

  • CCS FH position paper 2014 - Genest et al. Canadian Journal of Cardiology 30 (2014) 1471e1481
  • ESC position paper 2013 - Nordestgaard B G et al. Eur Heart J 2013;eurheartj.eht273

Beyond Statins Papers

  • IMPROVE-IT - Cannon. N Engl J Med. 10.1056/NEJMoa1410489. 1112
  • OSLER - Sabatine MS et al. N Engl J Med 2015; 372: 1500-9
  • ODYSSEY Long Term - Robinson J, et al. N Engl J Med. 2015;372(16):1489-99